(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Dr. Ma currently serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., ...

US pharma company Gilead Sciences is seeking regulatory ... He stressed that large-scale production and a robust supply chain were important for ensuring the drug reaches those who need it most.

U.S. pharma company Gilead Sciences is seeking regulatory ... He stressed that large-scale production and a robust supply chain were important to ensuring the drug reaches those who need it ...

These unrelated and geographically dispersed examples underscore the pharmaceutical industry's reliance on fragile supply chains ... during shortages. Gilead Sciences, Inc., a biopharmaceutical ...

Gilead Sciences plans to begin regulatory processes by the end ... Once approved, producing enough lenacapavir to create a reliable supply chain in Africa could be a significant challenge, according ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target ...

According to Babak Hodjat, CTO of AI at Cognizant, the Neuro AI platform has been tested, piloted and used for “almost any ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

MISSISSAUGA — Gilead Sciences Canada, Inc. (Gilead Canada) announced that Paul Petrelli joined the organization as Vice President and General Manager. In his new role, Petrelli will be ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen ...